Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma
Open Access
- 1 May 2004
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 15 (5) , 821-830
Abstract
Background: To evaluate the efficacy and feasibility of rituximab monotherapy in Japanese patients with relapsed or refractory aggressive B-cell lymphoma. Patients and methods: Sixty-eight patients were treated with rituximab at 375 mg/m2 by eight consecutive weekly infusions. Pretreatment variables affecting overall response rate (ORR) and progression-free survival (PFS) and the relationship between pharmacokinetic parameters and efficacy were analyzed. Results: The ORRs of 68 enrolled patients and 57 eligible patients were 35% [95% confidence interval (CI) 24% to 48%] and 37% (95% CI 25% to 51%), respectively. Median PFS of 53 evaluable patients was 52 days, whereas time to progression of 21 eligible responders was 245 days. Mild to moderate infusion-related toxicities were observed frequently at the first infusion, but all of them were reversible. Elevated lactate dehydrogenase (LDH) and refractoriness to prior chemotherapy were unfavorable factors affecting ORR and PFS (P P Conclusions: Eight consecutive weekly infusions of rituximab have significant anti-lymphoma activity for relapsed or refractory aggressive B-cell lymphoma. Several pretreatment variables and serum rituximab levels are useful for predicting its efficacy.Keywords
This publication has 29 references indexed in Scilit:
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- Practical Utility of the Revised European‐American Classification of Lymphoid Neoplasms for Japanese Non‐Hodgkin's LymphomasJapanese Journal of Cancer Research, 2000
- Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin’s lymphoma after high-dose therapy and autologous peripheral stem cell transplantationBone Marrow Transplantation, 1999
- A Novel DNA Virus (TTV) Associated with Elevated Transaminase Levels in Posttransfusion Hepatitis of Unknown EtiologyBiochemical and Biophysical Research Communications, 1997
- Immunohistochemical Analysis of Cyclin D1 Protein in Hematopoietic Neoplasms with Special Reference to Mantle Cell LymphomaJapanese Journal of Cancer Research, 1994
- Monoclonal Antibody against PRADl/Cyclin Dl Stains Nuclei of Tumor Cells with Translocation or Amplification at BCL‐1 LocusJapanese Journal of Cancer Research, 1994
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- Comparison of a Second-Generation Combination Chemotherapeutic Regimen (m-BACOD) with a Standard Regimen (CHOP) for Advanced Diffuse Non-Hodgkin's LymphomaNew England Journal of Medicine, 1992
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958